Navigation Links
Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia

SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation (000100.KS; Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced that they have entered into an agreement to form a joint venture company (JVC),  ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors. The creation of ImmuneOncia marks an important milestone in strengthening the presence of both companies in the dynamic field of immuno-oncology. Closing of the transaction is subject to customary closing conditions.

A recent report has predicted that the annual market for immunotherapies, consisting of anti-checkpoint antibodies, vaccines, and cell therapies, will exceed $35B while becoming the backbone of treatment for up to 60% of cancers over the next decade.1 ImmuneOncia will benefit from Sorrento's leading immunotherapy product portfolio as well as its manufacturing capabilities. The joint venture will also take advantage of Yuhan's world-class experience in research and development. ImmuneOncia will focus on advancing novel immunotherapies consistent with its mission of bringing safe and effective treatments for unmet medical needs to patients worldwide.

"The formation of ImmuneOncia represents a significant milestone for Yuhan as this is our first research and development-based joint venture company. Reflecting this importance, we are committing significant resources to ImmuneOncia for the development of novel cancer immunotherapies, an area of significant unmet need not just in Korea but also globally. Our JV will benefit immensely from Korea's world-renowned excellence and efficiency in drug development. We have strong interest in investing in Sorrento and its innovative immuno-oncology mAb portfolio, and look forward to working closely with Sorrento's outstanding team as well as further expanding our strategic relationship together," said Mr. Jung Hee Lee, President and CEO of Yuhan.

"We are excited to partner with Yuhan in jointly establishing ImmuneOncia," said Dr. Henry Ji, President and CEO of Sorrento. "This global joint venture enables Sorrento and Yuhan to combine our complementary strengths with the ultimate goal of developing and commercializing Sorrento's innovative immune checkpoint mAbs. Through joint ventures and strategic alliances, we continue to accelerate the resource-efficient development of Sorrento's diverse portfolio of immunotherapies into the clinic. We share Yuhan's enthusiasm for the potential of ImmuneOncia to develop a deep pipeline of immuno-oncology products for cancer patients worldwide."

Under the terms of the joint venture agreement (JVA), Yuhan will contribute an initial investment of USD $10 million to ImmuneOncia, and Sorrento will grant the JV an exclusive license for one of their immune checkpoint antibodies for specified countries while retaining the rights for US, European, and Japanese markets, as well as global rights for the JV to two additional antibodies that will be selected by ImmuneOncia from a group of pre-specified antibodies from Sorrento's immuno-oncology antibody portfolio. Yuhan will own 51% of ImmuneOncia, while Sorrento will hold the remaining 49%. Yuhan's Chief Scientific Officer Dr. Su Youn Nam will be appointed CEO of ImmuneOncia. The first of the three immune checkpoint antibodies is expected to enter clinical trials next year.

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

About Yuhan Corporation 

Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento's prospects, including, but not limited to any statements about the aforementioned immuno-oncology antibodies from Sorrento's antibody library;  Sorrento's ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

1 "Immunotherapy – The Beginning of the End for Cancer" issued by Dr. Andrew S. Baum, Citi Research, a division of Citigroup Global Markets Inc., in 2013.


Logo -
Logo -


SOURCE Sorrento Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Olympus Corporation of the Americas and Subsidiary Reach Settlement Agreements with U.S. Department of Justice
2. MGC Diagnostics Corporation to Report First Quarter Fiscal Year 2016 Financial Results on Tuesday, March 8, 2016
3. LifeScan Announces Strategic Collaboration with WellDoc Corporation to Advance Mobile Care Solutions for Type 2 Diabetes Patients
4. DURECT Corporation Announces Fourth Quarter 2015 Financial Results and Update of Programs
5. Global Pharmaceutical Filtration Market Value of USD 20,190.1 Million by 2020 - Analysis, Trends & Opportunities Report 2016-2020 - Key Vendors: General Electric, Pall Corporation, 3M
6. Luminex Corporation Announces Collaboration with University of Sao Paulo to Validate Zika Virus Detection Panel
7. United Orthopedic Corporation Announces Enrollment of First U.S. Patient in Hip Replacement System Follow-Up Study
8. Luminex Corporation Receives Medical Device License for ARIES System and ARIES HSV 1&2 Assay in Canada
9. Kahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities Litigation
10. DURECT Corporation Invites You to Join its Fourth Quarter 2015 Earnings Conference Call
11. Nipro Medical Corporation Launches the AQUALiner II Second Generation 0.035" Hydrophilic, Super-Elastic Nitinol Guidewire in the United States
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):